Calcitonin gene-related peptide (CGRP) is a sensory neuropeptide that also has potent vasodilator activity. There are conflicting preclinical reports regarding the effect of CGRP receptor antagonism in the setting of myocardial ischemia. The present study was conducted in a canine model in which regional myocardial ischemia was reproducibly evoked by serial periods of atrial pacing (80 beats per min above baseline rate) in the presence of a 40% stenosis of the left anterior descending (LAD) coronary artery. Ischemia severity was quantitated by changes in unipolar epicardial electrograms (EG) recorded in the area of ischemia. In validation studies, the calcium entry blocker diltiazem reduced ischemia severity (before versus after treatment: ⌬EG, 1.92 Ϯ 0.23 versus 0.54 Ϯ 0.24 mV; p Ͻ 0.05) and tended to increase LAD flow (7.7 Ϯ 0.7 versus 9.4 Ϯ 1.4 ml/min; p ϭ 0.10), whereas the coronary constrictor serotonin increased ischemia severity (before versus after treatment: ⌬EG, 2.11 Ϯ 0.44 versus 4.90 Ϯ 1.46 mV; p Ͻ 0.05) concomitant with a reduction in LAD flow (9.1 Ϯ 1.1 versus 5.4 Ϯ 1.5 ml/min; p Ͻ 0.05). A 30 g/kg/min i.v. infusion test dose of the CGRP receptor antagonist CGRP was validated by demonstrating complete block of the depressor effects of exogenous i.v. 0.03 to 0.3 g/kg CGRP. This dose of CGRP , administered either intravenously or intra-atrially, had no effect on ischemia severity or paced LAD flow, indicating no intrinsic effect of CGRP receptor antagonism on the severity of acute myocardial ischemia. Likewise, the administration of a hemodynamically active dosing regimen of CGRP (0.03 g/kg/min i.v.) had no effect on paced coronary flow or ischemia severity, suggesting no major role of CGRP in regulating ischemic blood flow.
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Calcitonin gene-related peptide (CGRP) is a sensory neuropeptide widely distributed throughout the central and peripheral nervous systems (Brain and Grant, 2004) . CGRP has been proposed to play a role in the pathophysiology of migraine based upon correlative changes in circulating CGRP concentrations during spontaneous and nitrate-induced migraine and during migraine treatment with triptans, as well as the provocation of headache with exogenous CGRP infusion in migraineurs (Edvinsson, 2007; Goadsby, 2008) . Clinical studies demonstrating efficacy with two CGRP receptor antagonists, the parenteral agent olcegepant (BIBN4096BS) (Doods et al., 2000; Olesen et al., 2004) and the orally available MK-0974 (telcagepant) (Ho et al., 2008; Salvatore et al., 2008) , have confirmed CGRP to be an important mediator of migraine.
CGRP also possesses direct and potent vasorelaxant properties (Brain and Grant, 2004) . In recognition of the vasodilatory properties of CGRP, as well as concerns regarding the cardiovascular liabilities of the currently available ergot and triptan migraine treatments (MaassenVanDenBrink et al., 1998; Wammes-van der Heijden et al., 2006) , multiple groups have conducted preclinical studies of the cardiovascular effects of CGRP receptor antagonism. There has been particular interest in the potential effect of CGRP receptor antagonism in the setting of myocardial ischemic injury, given that CGRP is stored in perivascular peripheral nerve terminals of sensory C-fibers in the heart and is released from activated peripheral nerve endings during myocardial ischemia (Franco-Cereceda and Liska, 2000) . Although the majority of previous in vivo and in vitro studies have reported no effect of Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.108.144220.
ABBREVIATIONS:
CGRP, calcitonin gene-related peptide; BIBN4096BS, olcegepant, -0974, telcagepant, N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-1-yl)piperidine-1-carboxamide; bpm, beats per minute; LAD, left anterior descending; EG, electrogram; HR, heart rate; MAP, mean arterial pressure.
CGRP receptor antagonism in the setting of myocardial ischemic injury (Kä llner et al., 1998 , Wu et al., 2001 Lu et al., 1999; Wang and Wang, 2005; Chai et al., 2006; Zhong and Wang, 2007) , some in vitro studies have suggested a potential detrimental effect (Lu et al., 1999; Chai et al., 2006; Zhong and Wang, 2007) depending on experimental protocol used. To date, no study has assessed the effects of CGRP receptor antagonism in an experimental myocardial ischemia paradigm permitting within-animal, pre-versus posttreatment assessment with concurrent positive and negative controls. The present study extends the assessment of the effects of CGRP receptor antagonism in the setting of myocardial ischemic injury through studies in a canine model in which regional myocardial ischemia is reproducibly elicited by serial periods of atrial pacing in the presence of coronary artery stenosis. Variations of this type of model have been used previously to study anti-ischemic agents (e.g., Grover and Parham, 1987; Sugiyama and Hashimoto, 1999) . The present studies expand the characterization of this preparation by showing it sensitive to both anti-and proischemic interventions using diltiazem and serotonin, respectively. Following model characterization, a pharmacodynamically validated dosing regimen of the standard CGRP peptide fragment receptor antagonist CGRP (Chiba et al., 1989) was tested and shown to have no effect on the severity of regional myocardial ischemia, indicating no intrinsic effect of CGRP receptor antagonism on the severity of acute myocardial ischemia. Likewise, the administration of a pharmacodynamically active dosing regimen of CGRP had no effect on paced coronary flow or severity of regional myocardial ischemia, suggesting no major role of CGRP in regulating ischemic blood flow.
Materials and Methods
All animal studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, 1996; National Institutes of Health Publication 80-23) and were approved by the Institutional Animal Care and Use Committee at Merck Research Laboratories (West Point, PA).
Surgical Preparation. Mongrel dogs (male or female; 10.3-15.2 kg, mean 12.3 Ϯ 0.2 kg) were anesthetized with 100 mg/kg i.v. ␣-chloralose and 5 mg/kg i.v. sodium pentobarbital (baseline sinus heart rate, 134.6 Ϯ 2.0 bpm). A continuous intravenous infusion of 10 mg/kg/h ␣-chloralose was used to maintain depth of anesthesia over the time course of the study. The animals were intubated and ventilated with room air. The right femoral artery and vein were cannulated for the measurement of mean arterial pressure and for maintenance of anesthesia, respectively. The left femoral vein was cannulated for intravenous test agent administration. A left thoracotomy was performed at the fifth intercostal space, and the pericardium incised to expose the heart. The left anterior descending (LAD) coronary artery was carefully dissected distal to the first major branch. A manual screw-occluder was placed loosely around the LAD, followed by the placement of a Doppler flow probe (1.5-2.5 mm; Transonic Systems Inc., Ithaca, NY) on the LAD distal to the occluder. Three unipolar electrodes were sutured to the anterior surface of the left ventricle adjacent to the LAD and distal to the occluder; these electrodes were used for the measurement of local myocardial ischemic changes. A bipolar electrode was sutured to the right atrium and used for controlling atrial rate. The left atrium was cannulated for intra-atrial test agent administration.
Experimental Protocol. The experimental protocol is depicted in Fig. 1 and consisted of three serial 5-min periods of atrial pacing at a fixed rate of 80 bpm greater than baseline sinus rate, with intervening periods of sinus rhythm. During the first 5-min period of atrial pacing (atrial pace baseline), paced LAD coronary flow and local cardiac electrograms (EGs) were recorded in the absence of coronary stenosis (i.e., screw-occluder not constricted). At the end of atrial pace baseline period measurements, the screw occluder was constricted to reduce paced LAD coronary flow by 40%, followed by cessation of atrial pacing and return to sinus rhythm for a period of 10 min. A second 5-min period of atrial pacing (atrial pace ischemic baseline) permitted the recording of paced LAD flow and local cardiac EGs during the 40% stenosis of the LAD in the absence of treatment. At the end of atrial pace ischemic baseline period measurements, atrial pacing was terminated and a 15-min period of sinus rhythm followed, with vehicle or test agent administration (intravenous or intra-atrial as described below) initiated after 10 min of sinus rhythm. All treatments, vehicle and active test agent, were administered over a period of 10 min, spanning the final 5 min of sinus rhythm and the third 5-min period of atrial pacing (atrial pace ischemic treatment). During this atrial pace ischemic-treated period, paced LAD flow and local cardiac EGs during a 40% stenosis of the LAD were recorded in the presence of treatment. Changes in paced LAD flow and local cardiac EG morphology (see below) constituted the main parameters relevant to test agent activity during atrial pacing-induced myocardial ischemia. As noted in Fig. 1 , in addition to the measurements noted above, measurements of heart rate, mean arterial pressure, and ECG intervals were made during periods of sinus rhythm (sinus baseline, sinus ϩ stenosis, and sinus ϩ stenosis treatment) for the purposes of model characterization as well as documenting the pharmacodynamic activity of test agents. Quantitation of Regional Myocardial Ischemia. Severity of regional myocardial ischemia was determined by analysis of STsegment changes in three to five consecutive complexes of the local cardiac unipolar electrograms during the three periods of rapid atrial pacing, essentially as described by Sugiyama and Hashimoto (1999) based on the guidance of Ellestad et al. (1996) . In the present study, the overwhelmingly most common atrial pace baseline morphology of local EG was that of an up-sloping ST-segment, with a deepening of ST-depression along with increases in S-and J-point amplitudes reflecting the development of regional myocardial ischemia resulting from atrial pacing in the presence of LAD stenosis (for examples, see Fig. 2 ). This profile is analogous to the increase in S wave amplitude during ischemic ST-segment depression in surface ECG observed in patients with stable angina (Glazier et al., 1987) . The S-point amplitude was found to be the clearest, most unambiguous point of measure and was used to quantitate local EG changes reflecting regional myocardial ischemia. Severity of regional ischemia in the absence of treatment was quantitated as the difference in local EG from the atrial pace ischemic baseline period relative to atrial pace baseline period. Severity of regional ischemia in the presence of treatment was quantitated as the difference in local EG from the atrial pace ischemic treatment period relative to atrial pace baseline period. Local EGs were recorded from three unipolar electrodes simultaneously in the LAD region distal to the occluder, with the one electrode displaying the clearest change in EG morphology during the atrial pace ischemic baseline then used for further comparison. ST-segment depression of Ͼ1 mV was the criterion for inclusion of an animal into the study. If none of the three local cardiac EG displayed a clear and sufficient change in morphology during the atrial pace ischemic baseline period, the study was terminated prospectively before vehicle or test agent administration. No attempt was made to alter the experimental conditions described above, including rate of atrial pacing or degree of LAD constriction, if there was no indication of pacing-induced regional ischemia during the atrial pace ischemic baseline period as recorded from the three preplaced unipolar electrodes. In the present series of studies, 12 preparations of 57 attempted (21%) were terminated before test agent administration due to lack of sufficient ischemia at baseline, with two additional preparations terminated due to technical failures.
Treatments and Dose Justification. Saline served as the vehicle for all test agents. In total, n ϭ 13 saline-treated animals (10 ml over 10 min i.v.) were run for combined model characterization as well as randomized during active test agent testing. Diltiazem (100 g/kg over 2 min ϩ 30 g/kg/min ϫ 8 min i.v.) (Sigma-Aldrich, St. Louis, MO) was chosen as an "anti-ischemic" control, having been reported previously to reduce the severity of regional ischemia in a similar model and dosing regimen (Grover and Parham, 1987) . Serotonin (3 g/kg/min ϫ 10 min i.a.) (Sigma-Aldrich) was chosen for assessment as a "proischemic" control based on a previous report of exacerbation of exercise-induced myocardial ischemia in dogs using a similar dose and route of administration (Guilbert et al., 2004) . As such, serotonin served not as a standard previously assessed in the same or similar type of preparation, but as an agent with high probability of proischemic potential based on previous literature. CGRP was used as a standard CGRP receptor antagonist (Chiba et al., 1989) . Previous studies in dogs have characterized continuous intravenous infusions of 20 to 30 g/kg/min CGRP as threshold doses for complete inhibition of responses to exogenous CGRP (Shen et al., 2001) . Accordingly, the 30 g/kg/min intravenous infusion test dose of CGRP ; Sigma-Aldrich] was internally validated as a CGRP pharmacologic blocking dose by demonstrating block of the depressor responses to bolus i.v. 0.03, 0.1, and 0.3 g/kg CGRP (human CGRP; Calbiochem, San Diego, CA) in conscious dogs. This 30 g/kg/min CGRP (8-37) infusion dose then was assessed both by intravenous and intra-atrial routes in the pacing-induced myocardial ischemia studies. Following the randomized assessments of saline vehicle, diltiazem, serotonin, and CGRP (8-37) described above, a temporally distinct group was administered CGRP (0.03 g/kg/ min ϫ 10 min i.v.; Sigma-Aldrich). This CGRP dosing regimen was based on a previous study reporting cardiac contractile effects in jpet.aspetjournals.org dogs (Atkins et al., 2000) but reduced slightly in the present study to produce a moderate approximately 20% decrease in mean arterial pressure, indicating the dosing regimen to be pharmacodynamically active.
Statistical Analysis. Data are expressed as mean Ϯ S.E.M. Comparisons of parameters at a given time point among multiple treatment groups, as well as within treatment group comparisons across more than two time points were conducted using a one-way analysis of variance, followed by a post hoc Fisher's protected least significant difference test. Directed within-treatment group comparisons of parameters measured in absence versus presence of treatment were conducted using a paired Student's t test.
Results

Canine Model of Atrial Pacing-Induced Myocardial Ischemia: Characterization
In total, 13 i.v. saline-treated animals were run for model development and randomized during active test agent assessment. Full saline experience in the preparation is summarized in Tables 1 and 2 . Sinus heart rate, mean arterial pressure, and ECG PR, QRS, and QTc intervals did not vary significantly over the time course of study in the absence versus presence of LAD stenosis and before and during saline infusion, reflecting preparation stability. LAD coronary flow increased significantly during the atrial pace baseline compared with sinus baseline, consistent with increased metabolic demand. By design, paced LAD coronary flow was reduced approximately 40% by constriction of the screwoccluder at the end of the atrial pace baseline period, and it remained equivalently reduced during the subsequent atrial pace ischemic baseline and saline-infused atrial pace ischemic treatment periods, indicating stable coronary artery flow reductions in the preparation. Equivalent approximately 2-mV changes in local cardiac electrograms were observed during the atrial pace ischemic baseline and the saline-infused atrial pace ischemic treatment periods ( Fig. 2A) , indicating reproducible production of regional myocardial ischemia.
Canine Model of Atrial Pacing-Induced Myocardial Ischemia: Test Agent Effects
Diltiazem and Serotonin. Table 3 summarizes sinus heart rate, mean arterial pressure, and ECG PR, QRS, and QTc data for saline, diltiazem, serotonin, and CGRP treatment groups during the sinus ϩ stenosis and sinus ϩ stenosis treatment periods. Values for sinus heart rate, mean arterial pressure, and ECG did not vary significantly among treatment groups during both the sinus baseline period (data not shown) as well as during the sinus ϩ stenosis period, indicating equivalence across groups. As noted above, intravenous saline had no effect on hemodynamic and ECG parameters. Diltiazem intravenously significantly reduced mean arterial pressure and prolonged PR interval, whereas having no effect in this dosing regimen on heart rate, QRS, and QTc interval. A reduction in mean arterial pressure, with no change in heart rate or ECG intervals, also was observed with intra-atrial serotonin. Table 4 summarizes paced LAD coronary flow for saline, diltiazem, serotonin and CGRP treatment groups during the atrial pace ischemic baseline and atrial pace ischemic treatment periods. LAD flows did not vary significantly among treatment groups during the sinus baseline and atrial pace baseline periods and immediately after establishment of the LAD stenosis (data not shown), as well as during the atrial pace ischemic baseline period (Table 4) , indicating equivalence across groups. As noted above, intravenous saline had no effect on paced LAD coronary flow. Diltiazem intravenously tended to increase paced LAD flow approximately 20% (p ϭ 0.10), whereas intra-atrial serotonin significantly reduced paced LAD coronary flow approximately 40% (p Ͻ 0.05). Table 4 also summarizes changes in local cardiac EG for saline, diltiazem, serotonin, and CGRP treatment groups during the atrial pace ischemic baseline and atrial pace ischemic treatment periods. Figure 2 provides examples of local cardiac EGs recorded in the treatment groups. Changes in local EG did not vary significantly among treatment groups during the atrial pace ischemic baseline period (Table 4) , indicative of equivalent production of regional myocardial ischemia among groups. As noted above, intravenous saline had no effect on changes in local cardiac EG, indicating no effect on severity of regional ischemia. Diltiazem intravenous significantly decreased changes in local cardiac EG approximately 70% (p Ͻ 0.01), indicative of a reduction in ischemia severity concordant with a tendency to increase coronary flow. Conversely, intra-atrial serotonin significantly increased changes in local cardiac EG approximately TABLE 1 Saline vehicle profile: effect of intravenous saline treatment (10 ml over 10 min i.v.) on HR, MAP, and ECG intervals (PR, QRS, and QTc) during sinus rhythm in the absence and presence of an LAD stenosis. Data are mean Ϯ S.E.M., with n ϭ 13. No cardiac rhythm abnormalities were observed during the administration of saline (n ϭ 13) or diltiazem (n ϭ 6) in the setting of LAD stenosis and atrial pacing. In the treatment group administered serotonin (n ϭ 6), one animal developed ventricular fibrillation at the very end of treatment infusion during LAD stenosis and atrial pacing.
CGRP . Figure 3 summarizes the dose-validation study for the CGRP (8-37) infusion test dose. The dose validation study demonstrated reproducible, equivalent systemic depressor responses to bolus intravenous 0.03 to 0.3 g/kg CGRP (maximal depressor response approximately 25 mm Hg) before and during saline infusion. The depressor response to CGRP was completely blocked during intravenous infusion of 30 g/kg/min CGRP . This infusion dose of CGRP had no effect on heart rate or ECG intervals (data not shown). This 30 g/kg/min CGRP (8-37) infusion dose then was assessed both by intravenous and intra-atrial routes in the atrial pacing-induced myocardial ischemia studies. Administered by both intravenous and intra-atrial routes, 30 g/kg/min CGRP (8-37) had no effect on heart rate, mean arterial pressure, or ECG intervals (Table 3 ) and no effect on paced LAD coronary flow (Table 4) . CGRP intravenously and intra-atrially also had no effect on changes in local cardiac EG ( Fig. 2; Table 4 ), indicating no effect on the severity of regional ischemia. No cardiac rhythm abnormalities were observed during the administration of CGRP (8-37) (total n ϭ 12, both intravenous and intra-atrial routes) in the setting of LAD stenosis and atrial pacing.
CGRP. Table 5 summarizes sinus heart rate, mean arterial pressure and ECG PR, QRS, and QTc data for the temporally distinct CGRP treatment group during the sinus ϩ stenosis and sinus ϩ stenosis treatment periods. Values for sinus heart rate, mean arterial pressure, and ECG intervals in the CGRP group varied slightly but not significantly compared with the treatment groups noted above (Table 3) during both the sinus baseline period (data not shown) and during the sinus ϩ stenosis period, indicating equivalence across all groups in these studies. Intravenous CGRP significantly reduced mean arterial pressure approximately 20% and increased heart rate approximately 13%, the latter probably a reflex response to the blood pressure lowering. CGRP had no effect on ECG intervals. Table 6 summarizes paced LAD coronary flow as well as changes in local cardiac EG for the CGRP group during the atrial pace ischemic baseline and atrial pace ischemic treatment periods. LAD flows in the CGRP group varied slightly but not significantly compared with the earlier treatment groups (Table 4) during the sinus baseline and atrial pace baseline periods and immediately after establishment of the LAD stenosis (data not shown), as well as during the atrial pace ischemic baseline period (Table 6 ), indicating equivalence across all groups in these studies. Likewise, changes in local EG did not vary significantly among the CGRP group and earlier treatment groups (Table 4) during the atrial pace   TABLE 4 Effects of saline (10 ml over 10 min i.v.), diltiazem (100 g/kg over 2 min ϩ 30 g/kg/min ϫ 8 min i.v.), serotonin (3 g/kg/min ϫ 10 min i.a.), CGRP (30 g/kg/min ϫ 10 min i.v.), and CGRP (8-37) (30 g/kg/min ϫ 10 min i.a.) on LAD coronary artery flow and local cardiac EG changes relative to atrial pace baseline during atrial pacing in the presence of an LAD stenosis Data are mean Ϯ S.E.M., with n ϭ 13 for saline and n ϭ 6 for test agents. Effects of saline (10 ml over 10 min i.v.), diltiazem (100 g/kg over 2 min ϩ 30 g/kg/min ϫ 8 min i.v.), serotonin (3 g/kg/min ϫ 10 min i.a.), CGRP 
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jpet.aspetjournals.org ischemic baseline period, indicative of equivalent production of regional myocardial ischemia among groups. Intravenous CGRP had no effect on paced LAD coronary flow and no effect on changes in local cardiac EG (Table 6 ), indicating no effect on the severity of regional ischemia. No cardiac rhythm abnormalities were observed during the administration of CGRP (n ϭ 6) in the setting of LAD stenosis and atrial pacing.
Discussion
The present study used a canine model in which regional myocardial ischemia was reproducibly evoked by serial periods of atrial pacing in the presence of coronary artery stenosis. Variations of this model have been used previously to assess anti-ischemic interventions of differing mechanisms (e.g., Grover and Parham, 1987; Sugiyama and Hashimoto, 1999) . Consistent with historical experience in this type of preparation (Grover and Parham, 1987) , a pharmacologic dosing regimen of the calcium entry blocker diltiazem (as reflected in an increased PR interval and deceased mean arterial pressure) tended to increase coronary flow in the setting of fixed stenosis and significantly reduced the severity of regional ischemia, validating this model for demonstrating anti-ischemic effects. To our knowledge, the present studies are the first to report a significant exacerbation of myocardial ischemia concomitant with decreased coronary flow using the coronary vasoconstrictor serotonin in this type of preparation, validating the model for demonstrating proischemic effects. Having demonstrated the sensitivity of this preparation to both anti-and proischemic effects, a pharmacodynamically validated dosing regimen of the CGRP receptor antagonist CGRP was tested and shown to have no effect on paced coronary flow or severity of regional myocardial ischemia. Likewise, the administration of a pharmacodynamically active dosing regimen of CGRP had no effect on paced coronary flow or ischemia severity.
Dog and human share important similarities regarding cardiac CGRP distribution and physiology. In both species, CGRP-immunoreactive nerve fibers preferentially innervate coronary arteries (Sugiyama et al., 1989; Gulbenkian et al., 1993) . Binding studies have reported abundant CGRP receptor localization in coronary arteries with low-to-no binding in working myocardium in both species (Coupe et al., 1990; Katori et al., 2005) . In vitro, CGRP potently relaxed human and dog epicardial coronary arteries (Gulbenkian et al., 1993; Quebbeman et al., 1993) . In vivo, exogenous CGRP exerted systemic depressor (Franco-Cereceda et al., 1987; Shen et al., 2001) and coronary vasodilator effects with greater effect on coronary diameter observed in larger versus smaller vessels in both species (Ludman et al., 1991; Sekiguchi et al., 1994) . These observations support dog as a relevant species for assessing CGRP antagonist cardiovascular effects in relation to similarity to human.
The dog model of pacing-induced myocardial ischemia in the setting of coronary stenosis simulates the clinical procedure of rapid atrial pacing stress testing in coronary artery disease patients used to demonstrate and determine anginal threshold (Feldman et al., 1996) . Extending the similarity between the preclinical model and clinical procedure, the use of local cardiac electrograms to quantitate regional myocardial ischemia as used in the dog model also has been used to increase the sensitivity of measurement of myocardial ischemia during atrial pacing in ischemic heart disease patients (Nabel et al., 1988) . The dog model of atrial pacing-induced myocardial ischemia in the setting of coronary stenosis possesses the following design features: the reproducible generation of myocardial ischemia during serial periods of atrial pacing allows for within animal analysis of pre-versus posttreatment effects; experimental protocol permits the identification and pretreatment exclusion of a minority of preparations that do not develop sufficient regional myocardial ischemia; and the model permits the simultaneous measurement of coronary blood flow and ischemia severity for both controls and test agents.
Although exogenous CGRP has been shown to produce potent systemic and coronary vasodilator effects, studies to date with the CGRP peptide fragment receptor antagonist CGRP and the nonpeptide BIBN4096BS in vivo in normal, unstressed rat, dog, and pig have reported no effect of CGRP receptor antagonism on coronary or regional myocardial blood flow (Shen et al., 2001; Kapoor et al., 2003; Arulmani et al., 2004) . The present findings with intravenous and intra-atrial CGRP extend these previous findings by demonstrating no effect of CGRP receptor antagonism on coronary flow during cardiac stress produced by rapid atrial pacing and coronary stenosis. One previous study in anesthetized dogs reported no effect of topically administered CGRP onto the left ventricular surface on coronary artery microvessel diameter before and at 10 min after LAD coronary artery occlusion (Sekiguchi et al., 1994) . The present study extends the latter findings by demonstrating no effect on coronary flow with systemically administered CGRP (8-37) during both coronary constriction and atrial pacing, as well as demonstrating no effect on a functional measure of ischemia severity. The present findings indicating no effect of CGRP receptor antagonism on the severity of regional myocardial ischemia are generally consistent with in vivo studies of CGRP and BIBN4096BS in rat and pig reporting no effect on coronary ischemia/reperfusion infarct size (Kä llner et al., 1998; Wu et al., 2001 ). Likewise, in vitro studies in isolated mouse and rat hearts have reported no effect of CGRP and BIBN4096BS on postischemia/reperfusion cardiac function, creatine kinase release or infarct size (Lu et al., 1999; Wang and Wang, 2005; Chai et al., 2006; Zhong and Wang, 2007) . It is noteworthy that some in vitro studies in isolated mouse and rat hearts, although demonstrating no intrinsic effect of CGRP receptor antagonism on ischemic injury or function, have reported an attenuation of ischemic preconditioning cardioprotection elicited by a set program of ischemia-reperfusion cycles preceding longer periods of myocardial ischemia (Lu et al., 1999; Chai et al., 2006; Zhong and Wang, 2007) . To date, the effect of CGRP receptor antagonism on ischemic preconditioning has been demonstrated only in isolated rodent hearts, and the pathophysiologic significance of this observation is uncertain.
Concerns regarding the potential effects of CGRP receptor antagonism in the setting of myocardial ischemia stem primarily from the localized storage of CGRP in perivascular peripheral nerve terminals of sensory C-fibers in the heart, and the demonstration of CGRP release from the activated peripheral nerve endings during myocardial ischemia (Franco-Cereceda and Liska, 2000) . Overall, the demonstration of CGRP release during myocardial ischemic injury clinically and preclinically has been mixed. Whereas an increase in coronary sinus CGRP concentration was reported in patients following coronary artery bypass grafting (Kä llner et al., 1999) , no changes in arterial CGRP concentration were observed in patients with angina or acute myocardial infarction (Wä hrborg et al., 1999) . In experimental studies, CGRP release into effluent has been reported in vitro in isolated rat and guinea pig hearts following global flow reductions (Franco-Cereceda et al., 1989; Burgdorf et al., 2005) . In vivo in rat, coronary artery occlusion followed by reperfusion resulted in a small, less than 2-fold increase in right ventricular blood CGRP concentration with no change in peripheral arterial CGRP concentration (Wu et al., 2001) . In vivo in pig, 45 min of coronary artery occlusion followed by 4 h of reperfusion resulted in no change in coronary sinus or peripheral arterial CGRP concentration (Kä llner et al., 1998) . To our knowledge there are no published reports on changes in local coronary or peripheral CGRP concentrations in dog myocardial ischemia models, and measurement of CGRP concentrations was not attempted in the present studies.
Published findings also are mixed with regard to the effects of exogenously administered CGRP in experimental myocardial ischemia models. In vitro in isolated mouse and rat hearts, global perfusion with CGRP has been reported to improve postischemic contractile recovery and/or reduce creatine kinase release and infarct size (e.g., Wang and Wang, 2005; Chai et al., 2006) . In contrast, in vivo in pigs subjected to 45 min of coronary artery occlusion followed by 4 h of reperfusion, CGRP had no effect on infarct size or on cardiac contractile function (Kä llner et al., 1998) . The present demonstration of no effect of CGRP on the severity of regional ischemia in vivo in the dog is consistent with the latter findings of Kä llner et al. (1998) .
Formally, the present finding of a lack of effect of CGRP receptor antagonism with CGRP on the severity of regional ischemia may reflect either a lack of CGRP release and/or lack of importance of released CGRP in this model. However, the combined demonstrations of lack of effects on paced coronary flow and ischemia severity with both CGRP and CGRP are consistent with no intrinsic effect of CGRP receptor antagonism on the severity of myocardial ischemia, and no major role played by CGRP, even if released, on the regulation of ischemic blood flow in this regional myocardial ischemia setting.
Several caveats and limitations to the present studies are acknowledged. Although existing literature indicates similarity between dog and human regarding cardiac CGRP distribution and physiology, it cannot be precluded that unidentified differences may exist in CGRP or CGRP receptor antagonist responses between these species. In the present study, a CGRP dosing regimen of 30 g/kg/min i.v. was internally validated and used as a CGRP-blocking dose; it cannot be excluded that lower doses of CGRP may have been equivalently effective CGRP blocking doses. Similar to the clinical diagnostic procedure of rapid atrial pacing stress testing, the present animal model assesses treatment effects in the setting of acute myocardial ischemia as opposed to chronic infarction; therefore, conclusions should be limited to the setting of acute myocardial ischemic injury. Finally, the present canine model assesses direct test agent effects during acute myocardial ischemia and is not designed to explore the phenomenon of preconditioning.
